Meeting
2020 Gastrointestinal Cancers Symposium
The comparison of mFOLFOXIRI with CAOX/SOX as neoadjuvant chemotherapy for locally advanced rectal cancer.
Authors
Tetsuji Terazawa
Department of Cancer Chemotherapy Center, Osaka Medical Collage Hospital, Osaka, Japan
Tetsuji Terazawa , Hiroyuki Kodama , Hiroki Yukami , Masahiko Aoki , Takahiro Miyamoto , Ken Asaishi , Toshifumi Yamaguchi , Takayuki Kii , Masahiro Goto , Keitaro Tanaka , Junji Okuda , Kazuhide Higuchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 51)
Abstract #
51
Poster Bd #
C1
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
First Author: Wen Zhang
Poster
2022 ASCO Gastrointestinal Cancers Symposium
SONCAR study: A prospective randomized controlled study on optimized neoadjuvant chemotherapy-oxaliplatin plus CRT in patients with locally advanced rectal cancer.
First Author: Rong-Xin Zhang
Poster
2016 ASCO Annual Meeting
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial.
First Author: Jean Baptiste Bachet
Poster
2016 Gastrointestinal Cancers Symposium
FOLFIRINOX for patients with borderline and never-resectable locally advanced pancreatic cancer, with the addition of chemoradiotherapy for potentially resectable patients: A phase II study.
First Author: Jon Kroll Bjerregaard